Cloudbreak Pharma Inc. has announced a supplemental grant of 3,000,000 Restricted Share Units (RSUs) under its Post-IPO Share Incentive Scheme. The RSUs have a performance target tied to the Group signing business development agreements totaling US$100 million in combined upfront payments and potential milestone payments. The performance target can be met in whole or in part based on the value of signed agreements, with RSUs vesting pro-rata as milestones are reached. The grant involves Whitcup Life Sciences LLC, a service provider wholly-owned by Dr. Scott Whitcup, which offers research, development, and business development services to the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260122-11997965), on January 22, 2026, and is solely responsible for the information contained therein.